Form 4: Viracta Therapeutics Director Acquires Shares Through Vesting of Restricted Stock Units

Director Roger Pomerantz acquired 9,034 shares of Viracta Therapeutics common stock through the vesting of restricted stock units.

Summary

• Roger Pomerantz, a director at Viracta Therapeutics, acquired 9,034 shares of common stock on November 25, 2024.
• The acquisition was a result of the vesting of restricted stock units (RSUs).
• Each RSU represents the right to receive one share of Viracta Therapeutics common stock.
• The RSUs were granted under the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan.
• The vesting schedule for the RSUs includes an initial vesting on November 25, 2021, followed by quarterly vesting dates on February 25, May 25, August 25, and November 25 of each year.
• Following the transaction, Mr. Pomerantz directly owns 126,478 shares of Viracta Therapeutics common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation. The vesting of shares is a positive sign of alignment between management and shareholders, but it is not a major event that would significantly impact the company's outlook.

Positives

• The vesting of RSUs aligns the director's interests with those of the shareholders.
• The director's increased shareholding demonstrates confidence in the company's future.

Industry Context

This is a standard transaction for a company that uses equity-based compensation for its directors and employees. It is common for directors to receive stock options or restricted stock units that vest over time.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as part of director compensation is a common practice in the biotechnology industry.
• Many companies, such as Amgen, Gilead Sciences, and Regeneron, use similar equity-based compensation plans to align the interests of their directors and employees with those of the shareholders.
• The vesting schedule of one-eighth initially and one-sixteenth quarterly is a fairly standard vesting schedule for RSUs.

Stakeholder Impact

• The vesting of shares increases the director's stake in the company, aligning their interests with those of shareholders.
• The transaction has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Viracta Therapeutics, insider trading, Form 4, restricted stock units, share acquisition, equity incentive plan, director, Roger Pomerantz, vesting